Klebsiella ESBL bacteremia-mortality and risk factors

Brazilian Journal of Infectious Diseases

Volumn 15, Issue 6, 2011, Pages 594-598

  Francisco Tuon, Felipe ^a   Kruger, Margot ^a   Terreri, Marcos ^a   Penteado Filho, Sergio R ^a   Gortz, Lucas ^a  

^a HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

Author keywords

Bacteremia; Beta lactamases; Carbapenems; Klebsiella pneumoniae

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BLOODSTREAM INFECTION; BRAZIL; CENTRAL VENOUS CATHETER; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTIVE SURGERY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BETA-LACTAMASES; CHILD; COHORT STUDIES; CROSS INFECTION; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84855930837     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(11)70257-4     Document Type: Article

References (18)

1. Girao E., Levin A.S., Basso M., et al. Trends and outcome of 1121 nosocomial bloodstream infections in intensive care units in a Brazilian hospital, 1999-2003. Int J Infect Dis 2008, 12:e145-e146.
2. Sader H.S., Jones R.N., Andrade-Baiocchi S., et al. Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagn Microbiol Infect Dis 2002, 44:273-280.
3. York M. Aerobic Bacteriology. Clinical Microbiology Procedures Handbook: 3. 17. 1-3. 17. 48. 2004, ASM Press, New York. H.I. Isenberg (Ed.).
4. Performance standards for antimicrobial disk susceptibility testing; Fifteenth Informational Supplement 2005, Clinical and Laboratory Standard Institute, Clinical and Laboratory Standard Institute, Wayne.
5. Marra A.R., Pereira C.A., Castelo A., et al. Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection. Int J Infect Dis 2006, 10:56-60.
6. Rossi F., Baquero F., Hsueh P.R., et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006, 58:205-210.
7. Kiffer C., Hsiung A., Oplustil C., et al. Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003. Braz J Infect Dis 2005, 9:216-224.
8. Paterson D.L., Ko W.C., Von G.A., et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended- spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004, 140:26-32.
9. Urbanek K., Kolar M., Loveckova Y., et al. Influence of thirdgeneration cephalosporin utilization on the occurrence of ESBL- positive Klebsiella pneumoniae strains. J Clin Pharm Ther 2007, 32:403-408.
10. Hyle E.P., Bilker W.B., Gasink L.B., et al. Impact of different methods for describing the extent of prior antibiotic exposure on the association between antibiotic use and antibiotic-resistant infection. Infect Control Hosp Epidemiol 2007, 28:647-654.
11. Calbo E., Romani V., Xercavins M., et al. Risk factors for community- onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006, 57:780-783.
12. Paterson D.L., Ko W.C., Von G.A., et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004, 140:26-32.
13. Marra A.R., Wey S.B., Castelo A., et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis 2006, 6:24.
14. Trecarichi E.M., Tumbarello M., Spanu T., et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009, 58:299-307.
15. Memon J.I., Rehmani R.S., Ahmed M.U., et al. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia Risk factors and outcome in the eastern region of Saudi Arabia. Saudi Med J 2009, 30:803-808.
16. Menashe G., Borer A., Yagupsky P., et al. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001, 33:188-193.
17. Du B., Long Y., Liu H., et al. Extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002, 28:1718-1723.
18. Paterson D.L., Ko W.C., Von G.A., et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004, 39:31-37.